Background: Cardiac tamponade is a serious complication of catheter ablation for
| INTRODUC TI ON
The effectiveness of catheter ablation therapy for atrial fibrillation (AF) is well-established. However, for maximum benefit, a reduction in acute procedure-related complications is essential.
In recent years, the number of AF ablation procedures has been increasing worldwide. Correspondingly, the incidence of cardiac tamponade, a serious complication of catheter ablation, is also increasing. However, there is little midterm follow-up research on patients of cardiac tamponade. In a large study, major complications related to AF ablation occurred in 4.54%-6% of patients. 1, 2 The mortality rate associated with AF ablation was 0.15%, 2 and cardiac tamponade was the most frequent cause of procedurerelated death. 3, 4 The incidence rate of cardiac tamponade is approximately 1%-1.31% but subsequent patient outcomes are not clear. 1, 2, 5 Further, the use of direct oral anticoagulants (DOAC) has recently increased all over the world. 6 The association between this change in anticoagulant therapy and cardiac tamponade is still unclear. In addition, although pericarditis sometimes occurs alongside cardiac tamponade, the relationship between them remains poorly understood. Distinctive cases of delayed cardiac tamponade after AF ablation have also been reported, [7] [8] [9] TA B L E 1 Clinical characteristics of 29 cardiac tamponade events AF, atrial fibrillation; AR, aortic regurgitation; ASD post ope, atrial septal defect postsurgical operation; BMI, body mass index; Complete, procedure could be completely ended; F, female; HOCM, hypertrophic obstructive cardiomyopathy; M, male; LAD, left atrial diameter; LSPerAF, long-standing persistent AF; LV-EF, left ventricular-ejection fraction; Not use, anticoagulant drug was not used before procedure; Onset, the time that cardiac tamponade occurred; PAF, paroxysmal AF; PerAF, persistent AF; VSA, vasospastic angina.
with rupture of an epicardial hematoma or pericarditis as the postulated causes. The aim of this study was to clarify the clinical characteristics and midterm outcomes of patients with cardiac tamponade.
| ME THODS

| Study participants
A total of 2467 sessions in which patients with AF and atrial tachycardia (AT) related to AF ablation, treated with catheter ablation between January 2007 and January 2016, were retrospectively enrolled in this study. 
| Ablation procedure and anticoagulation
Antiarrhythmic drugs were discontinued for at least five halflives before the procedure, with the exception of amiodarone.
Atrial thrombi were checked by transesophageal echocardiography on the day of (or the day before) the procedure. Surface electrocardiography (ECG) and intracardiac electrograms were continuously displayed and stored on a computer-based digital recording system using filter settings of 30-500 Hz during the procedure (CardioLab System; Prucka Engineering, Houston, TX, USA Anticoagulant therapy was prescribed before catheter ablation.
The attending physician selected the appropriate anticoagulant drug depending on age and renal function. Anticoagulant drugs were chosen among warfarin or factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) or direct oral thrombin inhibitors (dabigatran etexilate).
In the case of warfarin, the target prothrombin time-international normalized ratio (PT-INR) was set to 2.0-3.0 in patients younger than 70 years and 1.6-2.6 in those older than 70 years. 10 All patients underwent catheter ablation without interruption of warfarin or DOAC. Immediately following the transseptal puncture, 5000 units of intravenous heparin were given and heparinized saline was administered via sustained injection to maintain the activated clotting time at 300-400 s. Atrial blood pressure was monitored continuously from the 4 Fr sheath positioned within the right femoral artery.
| Definition of arrhythmia, cardiac tamponade, and pericarditis
Atrial arrhythmias were defined as supraventricular arrhythmias related to AF ablation, such as focal or macro-reentrant tachycardia at the left atrium. Common atrial flutter in the right atrium was excluded from this definition in this study. AF or AT related to prior AF ablation was assumed to be sustained for more than 2 h.
Cardiac tamponade was defined as an increase in pericardial effusion of >5 mm, a sign of collapse in the atrium or ventricle, and a decrease in systolic blood pressure to <80 mm Hg. Pericarditis was defined by both an increase in pericardial effusion of >5 mm at onset of cardiac tamponade and ST elevation >2 mm on >6 leads.
| Diagnosis and management of cardiac tamponade
If cardiac tamponade was suspected due to a decrease in blood pressure or unexpected catheter manipulation, the motion of the cardiac silhouette was checked in the left anterior oblique view. ter was introduced into the pericardial space and the pericardial fluid was drained. The drained blood was subjected to blood gas analysis to determine the presence of atrial or venous blood. The pericardial fluid was manually drained and connected to a closed drainage system. Heparin and warfarin were neutralized using protamine sulfate and vitamin K. The dabigatran neutralizer was not used in this study and the other DOAC do not have neutralizers, while all patients treated with warfarin received a vitamin K neutralizer. The patients were managed in the intensive care unit while the drainage catheter was within the pericardial space. After pericardial fluid flow stopped, the drainage catheter was removed and oral anticoagulant therapy was resumed.
| Definition of acute outcome, midterm outcome, AF/AT control, and follow-up
"Acute recurrence" was defined as AF/AT recurrence during the hospital stay for catheter ablation. "Midterm recurrence" was defined as AF/AT recurrence while the patient was being followed in the outpatient clinic or after any required repeat procedures. After discharge, patients were followed at 2 weeks, 1, 3, 6 months, and every 6 months thereafter at an outpatient clinic. Recurrences were investigated according to subjective symptoms, 12-lead ECG, Holter ECG (DSC-3300; Nihon Kohden, Tokyo, Japan), and an event recorder (HCG-901; Omron, Kyoto, Japan). Antiarrhythmic drugs were discontinued after catheter ablation at the discretion of the attending physician with input from the patient. "AF/AT control" was defined as the maintenance of sinus rhythm with or without antiarrhythmic drugs.
| Statistical analyses
Continuous variables are presented as means ± 1 standard deviation, and skewed variables are expressed as medians with interquartile ranges. Student's t test or the Mann-Whitney U tests were performed for two-group comparisons of continuous variables, as per Acute recurrence, AF/AT recurrence in acute term; AF, atrial fibrillation; AT, atrial tachycardia; BMI, body mass index; Complete procedure, procedure could be completely ended; DOAC, direct oral anticoagulants; EP, electrophysiological; Hospital stay, the length of hospitalization; LAD, left atrial diameter; LV-EF, left ventricular-ejection fraction; Max CRP, the maximum value of serum C-reactive protein; Midterm AF/AT control; AF/AT control in midterm; PAF, paroxysmal atrial fibrillation; Pre CRP, the preoperative serum C-reactive protein; Preventive administration, preventive administration for pericarditis; SD, standard deviation.
| RE SULTS
| Patients' characteristics
| Causes of cardiac tamponade
a
The number of the patients who took anticoagulant was 28, as one patient did not take it before catheter ablation. The number of this event was 19 of 28, as the drainage was not performed in seven, and the drainage blood type could not be evaluated in the remaining two events. *P < 0.05.
TA B L E 3
Comparison of clinical characteristics between warfarin group and DOAC group suite, four (4/29; 13.8%) during the ward stay after the procedure, and two events (2/29; 6.9%) at 10 and 33 days postprocedure. In 19 events (19/29, 65.5%) the ablation procedure was completed, and in 10 (10/29, 34.5%) it could not be completed on the first attempt.
There were no instances of cardiac tamponade associated with steam pops.
| Management of cardiac tamponade
Percutaneous pericardial puncture was performed in 21 events and seven events underwent conservative treatment without puncture. In one event, the puncture could not be performed because of anatomical difficulties (Event 12; Table 2 ). The average volume of initially drained blood was 408 ± 345 mL (21 events; range, 100-1300 mL; Table 1 ) and the drain pigtail catheter was placed for an average of 2.5 ± 1.1 days (20 events; range, 0-5 days; 
| Acute and midterm recurrence
The results of the acute and midterm recurrence of catheter ablation in patients with cardiac tamponade are shown in Figure 1 . Among the 19 events of cardiac tamponade, in which catheter ablation was completed, seven events developed acute recurrence of AF or AT (7/19, 36.8%; Table 2 ). Repeat sessions were performed in the 10 events in which the procedure was not completed and in two in which there was
TA B L E 4 Comparison of clinical characteristics between pericarditis group and nonpericarditis group
Demographic variables
All events n = 29
Pericarditis group n = 10
Nonpericarditis group n = 19 P value
Age (y ± SD) 64. The number of this event was 19 of 29, as the drainage was not performed in seven, and the drainage blood type could not be evaluated in the remaining three events. *P < 0.05; **P < 0.005. AF/AT recurrence over blanking periods of 3 months. Optimal medical therapy was administered in 11 events (37.9%, 11/29; 3 PAF, 4 PerAF, 4 LSPerAF; Table 2 ) at the discretion of the attending physician in consultation with the patient. By midterm follow-up (3.1 ± 2.6 years), 27 of 29 events were free from AF or AT (nine with medication). Other major complications such as death, congestive heart failure, or stroke
were not observed during the follow-up period.
| Anticoagulant therapy
Anticoagulant therapy was administered in 28 events (96.6%) before catheter ablation (Table 1) . Among them, 21 events received warfarin, and seven events received factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) or direct oral thrombin inhibitors (dabigatran etexilate). There was no significant difference in the clinical characteristics and outcomes between the warfarin and DOAC groups. No significant differences in drained blood volume (warfarin group, 340 ± 240 mL vs DOAC group, 417 ± 393 mL; P = 0.598) and hospital stay (warfarin group, 11.7 ± 7.53 days, vs DOAC group, 9.9 ± 4.95 days; P = 0.560) were observed. Only the rate of venous blood tamponade was significantly higher in the DOAC group [5/5 (100%) vs 7/14 (50.0%); P = 0.047; Table 3 ]. The acute and midterm recurrence rates of AF were not significantly different (Table 3 ).
| Pericarditis associated with cardiac tamponade
Among all 29 events, 10 (10/29; 34.5%) developed pericarditis.
Most cases of pericarditis developed immediately after cardiac tamponade; however, one developed after discharge from the hospital ( Table 2 ; Event 20). Patients with pericarditis exhibited more severe disease statuses than those without (Table 4) . The maximum C-reactive protein values were higher in the cardiac tamponade with pericarditis group than in the cardiac tamponade without pericarditis group (12.32 ± 7.8 vs 3.71 ± 3.0 mg/dL; P = 0.0002). The mean hospitalization was also longer in the pericarditis group (14.3 ± 4.6 vs 10.2 ± 7.8 days; P = 0.0048). In contrast, there was no statistically significant difference in midterm outcome between the two groups (with pericarditis, 0/10 events, 0.0%; without pericarditis group, 2/19 events, 10.5%; P = 0.288). Anti-inflammatory drugs, such as nonsteroidal antiinflammatories (NSAIDs), or steroids were administered at the attending physician's discretion in 15 events to prevent pericarditis ( Table 2 ). The amount of blood drained in the pericarditis group was higher than that in the nonpericarditis group (680 ± 485 mL vs 272 ± 124 mL; P = 0.071). The incidence rate of pericarditis was lower in the group that received prophylactic treatment than in the group that did not (2/15 events, 13.3% vs 8/14 events, 57.1%; P = 0.013; odds ratio, 0.115; 95% confidence intervals, 0.019-0.717).
| Delayed tamponade
In this study, only two events developed delayed tamponade (2/2467, 0.081%). In one event, the patient noticed chest discomfort 10 days after catheter ablation. He visited the emergency room after discharge and pericardial effusion was confirmed via echocardiography ( Figure 2A ). After pericardiocentesis, there was no reaccumulation of effusion. In another event, cardiac tamponade occurred immediately after PV isolation by cryoballoon and pericardiocentesis was performed at once. Pericarditis occurred 2 days after catheter ablation. NSAIDs and colchicine were prescribed, and after resolution of the pericarditis, the patient was discharged. However, 33 days after catheter ablation, he experienced new-onset dyspnea and presented to the emergency department. We observed increased pericardial fluid and inflow blockage on the echocardiogram, diagnosed him with recurrent cardiac tamponade and performed a repeat 
| D ISCUSS I ON
| Main findings
To the best of our knowledge, this study describes the longest follow-up period for patients with cardiac tamponade associated with ablation for AF. In addition, only a few reports have described pericarditis in patients with cardiac tamponade and the relationship between DOAC and cardiac tamponade. Among the patients with cardiac tamponade in our study, seven events (24.1%)
were prescribed DOAC. The acute and midterm recurrence rate
were not significantly different in the DOAC and warfarin groups.
Pericarditis occurred in 10 events (34.5%) and 17 (58.6%) had an AF/ AT recurrence during their respective hospital stays (An example of AF recurrence with pericarditis is shown in Figure 2B) . None of the patients required surgical treatment. During midterm follow-up (3.1 ± 2.6 years), 27 events were free from AF or AT (27/29; 93.1%, nine events with antiarrhythmic medication).
| Acute and midterm outcome in cardiac tamponade cases
While previous studies have reported frequency of cardiac tamponade, midterm outcomes are lacking. In this study, the overall acute AF/AT recurrence rate was 58.6% (17/29). In 19 events that underwent complete ablation, the acute AF/AT rate was 36.8% (7/19 (Table 5) , which reported a high rate of sinus rhythm maintenance in midterm (7/9, 77.8%, 1 patient with antiarrhythmic drug, 1.5 ± 1.1 years follow-up). However, it bears mentioning that these favorable results were achieved at a high volume center with expert electrophysiologists.
| Causes of cardiac tamponade
A previous paper had reported that steam pops can cause cardiac tamponade during ablation of ventricular arrhythmias, and that surgical repair was often needed. 12 Although cardiac tamponade attributable to steam pop was also reported during AF ablation, 4 no such incidents occurred in this study. This may be due to the magnitude of energy applied, which is limited to 35 W at our institution. Atrial bleeding could be caused by injury to the left atrial appendage, left atrial roof, or PVs.
In contrast, venous bleeding occurs secondary to damage the right atrium, right ventricle, or coronary sinus. This indicates the importance of catheter manipulation in the right side of the heart as well as the left side during AF ablation in patients on anticoagulation.
| Anticoagulant therapy
The standard procedures for catheter ablation are changing and the number of patients requiring AF ablation continues to increase worldwide. It is common to perform AF ablation while continuing anticoagulant therapy. As long as the PT-INR is maintained within the appropriate range, bleeding complications are rare, even with warfarin treatment. 12 All our patients underwent catheter ablation while on anticoagulant therapy. This study is the first report to describe pericarditis and cardiac tamponade related to AF ablation in patients receiving anticoagulant therapy, including DOAC. Similar to past reports of warfarin use in 11, 13 cardiac tamponade, DOAC may be fully manageable if proper supports are given.
| Pericarditis with cardiac tamponade
A case of pericarditis complicated with cardiac tamponade was previously reported by Bunch et al 11 in a study where 8 of 15 patients (53.3%) developed pericarditis (Table 5 ). In our study, 10 events (10/29, 34.5%) developed pericarditis after cardiac tamponade ( Table 4 ). The events with pericarditis required longer hospital stays (14.3 ± 4.6 days). Subsequent pericarditis was less frequent in the group that received prophylactic treatment than in the group that did not (2/15, 13.3% vs 8/14, 57.1%; P = 0.013). The cause of pericarditis after cardiac tamponade is still unclear. The maximum value of serum C-reactive protein was higher in the pericarditis group (12.32 ± 7.8 vs in nonpericarditis Group, 3.71 ± 3.0, P = 0.0002; Table 4 ), presumably caused by the pericarditis itself. Although there was no significant difference in the drainage volume between the two groups (680 ± 485 mL in pericarditis group vs 272 ± 124 mL in nonpericarditis group; P = 0.071), pericarditis tended to occurs when the volume exceeded 600 mL. In such circumstances, the administration of anti-inflammatory drugs should be considered to prevent pericarditis.
| Delayed tamponade
Similarly to "Dressler syndrome" and "postcardiac injury syndrome," late-onset pericarditis after catheter ablation has been reported. [14] [15] [16] The onset of these conditions can vary from within a few days to a few weeks after procedure. Although the pathogenesis is unclear, inflammation of the ablation region or rupture of a hematoma on the pericardial side are possible causes of this rarecomplication. 7 In this study, only two events developed delayed tamponade (2/2467, 0.081%). Both patients had been checked for excess pericardial fluid before discharge; therefore, we suspect that the pericardial effusion increased during the postdischarge subacute phase. Even at several weeks after the procedure, it is necessary to pay attention to changes in the patient's physical condition as there is a possibility, albeit low, that delayed tamponade will occur.
| Limitations
The study has some limitations. First, we retrospectively examined a small (29) number of events from a single center. Second, the AF/ AT recurrences were diagnosed based on the patient's symptoms and regular follow-up 12-lead ECGs, 24-h Holter monitoring, or event recordings. Recurrence after ablation can be asymptomatic and we, therefore, may have missed some cases. Third, we used the contact force system in only 10 events because of insurancerelated concerns. The use of a contact force system may affect the occurrence of cardiac tamponade as its incidence may be decreased if excessive contact is avoided. Finally, the rate of occurrence of cardiac tamponade depends on the experience of both the operator and the institute. Thus, in a different setting, the results may differ.
| CON CLUS ION
Cardiac tamponade is a serious complication of the catheter ablation procedure for AF, and acute AT/AF recurrence and pericarditis are quite common. If the ablation procedure can be completed before the occurrence of cardiac tamponade, or a repeat ablation procedure scheduled later, the midterm outcomes of AF ablation may be unaffected.
